It has been shown that blocking IL-6 enhances the therapeutic effect of immunotherapy by inducing and recruiting higher levels of CD4 + /CD8 + effector T cell production and recruitment in the tumor microenvironment (Hailemichael et al. 2022). The gene discussed is CD8A; the disease is neoplasm.